Skip to main content

GT Biopharma Inc

For the period ended Dec 31, 2024. Filed Feb 21, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 21, 2025

GTBP$3.96-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Power of Attorney (included on signature page)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Breen and Alan Urban, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution for him, and in his name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

NamePositionDate
/s/ Michael BreenExecutive Chairman of the Board andFebruary 21, 2025
Michael BreenInterim Chief Executive Officer (Principal Executive Officer)
/s/ Alan UrbanChief Financial OfficerFebruary 21, 2025
Alan Urban(Principal Financial and Accounting Officer)
/s/ Bruce WendelVice Chairman of the BoardFebruary 21, 2025
Bruce Wendel
/s/ Rajesh ShrotriyaDirectorFebruary 21, 2025
Rajesh Shrotriya, M.D.
/s/ Charles CasamentoDirectorFebruary 21, 2025
Charles Casamento
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.